Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis

JAMA

Volumn 276, Issue 4, 1996, Pages 285-292

  Danese, Mark D ^a   Powe, Neil R ^a,b,c   Sawin, Clark T ^e,f   Ladenson, Paul W ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Divisions of General Internal Medicine   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LEVOTHYROXINE SODIUM; THYROTROPIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; THYROID DISEASE; THYROTROPIN BLOOD LEVEL;

EID: 0029888196     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.4.285     Document Type: Article

References (61)

1. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7: 481-493.
2. Falkenberg M, Kagedal B, Norr A. Screening of an elderly female population for hypo- and hyperthyroidism by use of a thyroid hormone panel. Acta Med Scand. 1983;214:361-365.
3. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf). 1991;34:77-83.
4. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The ageing thyroid: thyroid deficiency in the Framingham study. Arch Intern Med. 1985;145:1386-1388.
5. Nyström E, Bengtsson C, Lindquist O, Noppa H, Lindstedt G, Lundberg PA. Thyroid disease and high concentration of serum thyrotrophin in a population sample of women: a 4-year follow-up. Acta Med Scand. 1981;210:39-46.
6. Franklyn J. 'Subclinical hypothyroidism.' Clin Endocrinol (Oxf). 1995;43:443-444.
7. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43:55-68.
8. Geul KW, van Sluisveld ILL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middleaged women: associations with serum lipids. Clin Endocrinol (Oxf). 1993;39:275-280.
9. Tunbridge WMG, Brewis M, French JM, et al. Natural history of autoimmune thyroiditis. BMJ. 1981; 282258-262.
10. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly. JAMA. 1987;258: 209-213.
11. Gordin A, Lamberg BA. Spontaneous hypothyroidism in symptomless autoimmune thyroiditis. Clin Endocrinol (Oxf). 1981;15:537-543.
12. Bogner U, Arntz HR, Peters H, Schleusener H. Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified. Acta Endocrinol. 1993;128:202-206.
13. Miura S, Iitaka M, Yoshimura H, et al. Disturbed lipid metabolism in patients with Subclinical hypothyroidism: effect of L-thyroxine therapy. Intern Med. 1994;33:413-417.
14. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in Subclinical hypothyroidism. Ann Intern Med. 1984;101:18-24.
15. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism. Am J Med. 1992;92:631-641.
16. Nyström E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subelinical' hypothyroidism. Clin Endocrinol (Oxf). 1988;29:63-76.
17. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996.
18. Screening for thyroid disease. Lancet. 1981;2: 128-130. Editorial.
19. dos Remedios LV, Weber PM, Feldman R, Schurr DA, Tsoi TG. Detecting unsuspected thyroid dysfunction by the free thyroxine index. Arch Intern Med. 1980;140:1045-1049.
20. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121:1-45.
21. Riniker M, Tieche M, Lupi GA, Grob P, Studer H, Burgi H. Prevalence of various degrees of hypothyroidism among patients of a general medical department. Clin Endocrinol (Oxf). 1981;14:69-74.
22. Helfand M, Crapo LM. Screening for thyroid disease. Ann Intern Med. 1990;112:840-849.
23. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
24. Sonnenberg FA, Wong, JB. Commentary: fine-tuning life-expectancy calculations using Markov processes. Med Decis Making. 1993;13:170-172.
25. Miller DK, Homan SM. Determining transition probabilities. Med Decis Making. 1994;14:52-58.
26. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
27. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:515-517.
28. Ladenson PW, Wilson MC, Gardin J, et al. Relationship of subclinical hypothyroidism to cardiovascular risk factors and disease in an elderly population. Thyroid. 1994;4:5-16.
29. Franklyn JA, Daykin J, Betteridge J, et al. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol (Oxf). 1993;38:453-459.
30. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Arch Intern Med. 1990;150:2097-2100.
31. Arem R, Escalante DA, Arem N, Morrisett JD, Patsch W. Effect of L-thyroxine therapy on lipoprotein fraction in overt and subclinical hypothyroidism, with special reference to lipoprotein (a). Metabolism. 1995;44:1559-1563.
32. Bell GM, Todd WTA, Forfar JC, et al. End organ responses to thyroxine therapy in subclinical hypothyroidism. Clin Endocrinol (Oxf). 1985;22:83-89.
33. Ridgway EC, Cooper DS, Walker H, Rodbard D, Maloof F. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1981;53:1238-1242.
34. Diekman T, Lansberg PJ, Kasterlein JJP, Wiersinga WM. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med. 1995;155:1490-1495.
35. National Center for Health Statistics. Serum lipids of adults 20-74 years: United States, 1976-1980. Vital Health Stat 11. 1993;242.
36. Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism. Clin Invest. 1993;71: 367-371.
37. US Dept of Health, Education, and Welfare. Some characteristics related to the incidence of cardiovascular disease and death: 18-year follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: Public Health Service; 1973. Section 30.
38. US Dept of Health and Human Services. Some risk factors related to the incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. In: The Framingham Study; An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987. Section 34.
39. US Dept of Health and Human Services. Survival following initial cardiovascular events: 30-year follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1988. Section 35.
40. Wartofsky L. Myxedema coma. In: Braverman LE, Utiger RD, eds. The Thyroid. 6th ed. Philadelphia, Pa: JB Lippincott Co; 1991:1084-1091.
41. Physicians Current Procedural Technology: CPT '94. American Medical Association: Chicago Ill; 1994.
42. Redbook 1994. Montvale, NJ: Medical Economics Data; 1994.
43. IMS America, Totowa, NJ: 1994.
44. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA. 1990;264:3025-3033.
45. Denke MA, Grundy SM. Individual responses to a cholesterol lowering diet in 50 men with moderate hypercholesterolemia. Arch Intern Med. 1994; 154:317-325.
46. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328:1213-1219.
47. Wittels EH, Hay JW, Gotto. AM. Medical costs of coronary artery disease in the United States. Am J Cardiol. 1990;65:432-440.
48. Doubilet P, Abrams HL. The cost of underutilization: percutaneous transluminal angioplasty for peripheral vascular disease. N Engl J Med. 1984; 310:95-102.
49. Hunink MGM, Cullen KA, Donaldson MC. Hospital costs of revascularization procedures for femoropopliteal arterial disease. J Vasc Surg. 1994;19: 632-641.
50. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;26:1149-1156.
51. Smurawaska LT, Alexantrov AV, Bladin CR, Norris JW. Cost of acute stroke care in Toronto, Canada. Stroke. 1994;25:1628-1631.
52. Epstein KA, Schneiderman LJ, Bush JW, Zettner A. The 'abnormal' screening serum thyroxine (T4): analysis of physician response, outcome, cost and health effectiveness. J Chronic Dis. 1981;34:175-190.
53. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
54. Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol. 1991;67:1084-1089.
55. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke. 1994;25:1721-1725.
56. de Koning HJ, van Ineveld BM, van Oortmarssen GJ. Breast cancer screening and cost-effectiveness. Int J Cancer. 1991;49:531-537.
57. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Anst. 1992;156:312-316.
58. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health. 1988;78:1417-1421.
59. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med. 1990;112:192-202.
60. Toft AD. Thyroxine therapy. N Engl J Med. 1994;331:174-180.
61. Keating FR Jr, Parkin TW, Selby JB, Dickinson LS. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis. 1961;3:364-81.